Immunogenicity and safety of the quadrivalent human papillomavirus vaccine in HIV-1-infected women

Clinical Infectious Diseases

Volumn 59, Issue 1, 2014, Pages 127-135

  Kojic, Erna Milunka ^a   Kang, Minhee ^b   Cespedes, Michelle S ^c   Umbleja, Triin ^b   Godfrey, Catherine ^d   Allen, Reena T ^e   Firnhaber, Cynthia ^f   Grinsztejn, Beatriz ^g   Palefsky, Joel M ^h   Webster Cyriaque, Jennifer Y ⁱ   Saah, Alfred ^j   Aberg, Judith A ^c   Cu Uvin, Susan ^a  

^a BROWN UNIVERSITY   (United States)

^b CENTER FOR BIOSTATISTICS IN AIDS RESEARCH   (United States)

^c MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^d NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

^e ASSIST Coordinating Center   (United States)

^f UNIVERSITY OF THE WITWATERSRAND   (South Africa)

^g Funda??o Oswaldo Cruz   (Brazil)

^h UNIVERSITY OF CALIFORNIA   (United States)

ⁱ UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

^j MERCK RESEARCH LABORATORIES   (United States)

more..

Author keywords

anogenital disease; HIV infected women; HPV vaccine; immunogenicity; vaccine safety

Indexed keywords

WART VIRUS VACCINE; VIRUS ANTIBODY;

ADULT; ALLERGIC REACTION; ANTIBODY BLOOD LEVEL; APPLICATION SITE PAIN; ARTICLE; CD4 LYMPHOCYTE COUNT; CELL SCREENING; CLINICAL ASSESSMENT; CONTROLLED STUDY; DRUG SAFETY; FEMALE; FEVER; GASTROINTESTINAL DISEASE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN PAPILLOMAVIRUS TYPE 11; HUMAN PAPILLOMAVIRUS TYPE 16; HUMAN PAPILLOMAVIRUS TYPE 18; HUMAN PAPILLOMAVIRUS TYPE 6; IMMUNOASSAY; IMMUNOGENICITY; INJECTION SITE REACTION; MAJOR CLINICAL STUDY; MULTICENTER STUDY; NEUROLOGIC DISEASE; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; SEROCONVERSION; SEROLOGY; VIRUS LOAD; ADOLESCENT; ADVERSE DRUG REACTION; ADVERSE EFFECTS; BLOOD; BRAZIL; CLINICAL TRIAL; COMPLICATION; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNOLOGY; ISOLATION AND PURIFICATION; MIDDLE AGED; PAPILLOMAVIRIDAE; PAPILLOMAVIRUS INFECTIONS; PROCEDURES; SOUTH AFRICA; UNITED STATES; VACCINATION; YOUNG ADULT;

ADOLESCENT; ADULT; ANTIBODIES, VIRAL; BRAZIL; CD4 LYMPHOCYTE COUNT; DRUG-RELATED SIDE EFFECTS AND ADVERSE REACTIONS; FEMALE; HIV INFECTIONS; HIV-1; HUMAN PAPILLOMAVIRUS RECOMBINANT VACCINE QUADRIVALENT, TYPES 6, 11, 16, 18; HUMANS; MIDDLE AGED; PAPILLOMAVIRIDAE; PAPILLOMAVIRUS INFECTIONS; PAPILLOMAVIRUS VACCINES; SOUTH AFRICA; UNITED STATES; VACCINATION; VIRAL LOAD; YOUNG ADULT;

EID: 84903944942     PISSN: 10584838     EISSN: 15376591     Source Type: Journal    
DOI: 10.1093/cid/ciu238     Document Type: Article

References (25)

1. Bosch FX, Lorincz A, Munoz N, Meijer CJ, Shah KV. The causal relation between human papillomavirus and cervical cancer. J Clin Pathol 2002; 55:244-65.
2. Melbye M, Sprogel P. Aetiological parallel between anal cancer and cervical cancer. Lancet 1991; 338:657-9.
3. Abraham AG, Strickler HD, Jing Y, et al. Invasive cervical cancer risk among HIV-infected women: a North American multi-cohort collaboration prospective study. J Acquir Immune Defic Syndr 2013; 62: 405-13.
4. Hessol NA, Holly EA, Efird JT, et al. Anal intraepithelial neoplasia in a multisite study of HIV-infected and high-risk HIV-uninfected women. AIDS 2009; 23:59-70.
5. D'Souza G, Wiley DJ, Li X, et al. Incidence and epidemiology of anal cancer in the Multicenter AIDS Cohort Study. J Acquir Immune Defic Syndr 2008; 48:491-9.
6. Kojic EM, Cu-Uvin S, Conley L, et al. Human papillomavirus infection and cytologic abnormalities of the anus and cervix among HIV-infected women in the study to understand the natural history of HIV/AIDS in the era of effective therapy (the SUN study). Sex Transm Dis 2011; 38:253-9.
7. Patel P, Hanson DL, Sullivan PS, et al. Incidence of types of cancer among HIV-infected persons compared with the general population in the United States, 1992-2003. Ann Intern Med 2008; 148:728-36.
8. Cervical Cancer Global Crisis Card. Official reports by WHO, United Nations, The World Bank, IARC Globocan. Available at: http://www.who.int/ hpvcentre/statistics/en/. Accessed 15 April 2013.
9. Quadrivalent vaccine against human papillomavirus to prevent highgrade cervical lesions. N Engl J Med 2007; 356:1915-27.
10. Garland SM, Hernandez-Avila M, Wheeler CM, et al. Quadrivalent vaccine against human papillomavirus to prevent anogenital diseases. N Engl J Med 2007; 356:1928-43.
11. Giuliano AR, Palefsky JM, Goldstone S, et al. Efficacy of quadrivalent HPV vaccine against HPV infection and disease in males. N Engl J Med 2011; 364:401-11.
12. Palefsky JM, Giuliano AR, Goldstone S, et al. HPV vaccine against anal HPV infection and anal intraepithelial neoplasia. N Engl J Med 2011; 365:1576-85.
13. Clark LR, Myers ER, Huh W, et al. Clinical trial experience with prophylactic human papillomavirus 6/11/16/18 vaccine in young black women. J Adolesc Health 2013; 52:322-9.
14. Overton ET, Sungkanuparph S, Powderly WG, Seyfried W, Groger RK, Aberg JA. Undetectable plasma HIV RNA load predicts success after hepatitis B vaccination in HIV-infected persons. Clin Infect Dis 2005; 41:1045-8.
15. Shire NJ, Welge JA, Sherman KE. Efficacy of inactivated hepatitis Avaccine in HIV-infected patients: a hierarchical Bayesian meta-analysis. Vaccine 2006; 24:272-9.
16. Tayal SC, Sankar KN. Impaired response to recombinant hepatitis B vaccine in asymptomatic HIV-infected individuals. AIDS 1994; 8:558-9.
17. Weinberg A, Gona P, Nachman SA, et al. Antibody responses to hepatitis A virus vaccine in HIV-infected children with evidence of immunologic reconstitution while receiving highly active antiretroviral therapy. J Infect Dis 2006; 193:302-11.
18. Wilkin T, Lee JY, Lensing SY, et al. Safety and immunogenicity of the quadrivalent human papillomavirus vaccine in HIV-1-infected men. J Infect Dis 2010; 202:1246-53.
19. Kahn JA, Xu J, Kapogiannis BG, et al. Immunogenicity and safety of the human papillomavirus 6, 11, 16, 18 vaccine in HIV-infected young women. Clin Infect Dis 2013; 57:735-44.
20. Palefsky JM, Holly EA, Ralston ML, Jay N. Prevalence and risk factors for human papillomavirus infection of the anal canal in human immunodeficiency virus (HIV)-positive and HIV-negative homosexual men. J Infect Dis 1998; 177:361-7.
21. Joura EA, Kjaer SK, Wheeler CM, et al. HPV antibody levels and clinical efficacy following administration of a prophylactic quadrivalent HPV vaccine. Vaccine 2008; 26:6844-51.
22. Longet S, Schiller JT, Bobst M, Jichlinski P, Nardelli-Haefliger D. A murine genital-challengemodel is a sensitivemeasure of protective antibodies against human papillomavirus infection. J Virol 2011; 85:13253-9.
23. Roberts C, Swoyer R, Bryan J. Evaluation of the HPV 18 antibody response in Gardasil(R) vaccinees after 48 mo using a pseudovirion neutralization assay. Hum Vaccin Immunother 2012; 8:431-4.
24. Brown DR, Garland SM, Ferris DG, et al. The humoral response to Gardasil over four years as defined by total IgG and competitive Luminex immunoassay. Hum Vaccin 2011; 7:230-8.
25. Munoz N, Manalastas R Jr, Pitisuttithum P, et al. Safety, immunogenicity, and efficacy of quadrivalent human papillomavirus (types 6, 11, 16, 18) recombinant vaccine in women aged 24-45 years: a randomised, double-blind trial. Lancet 2009; 373:1949-57.